UpdatesPress Release
Dr Lal PathLabs reported Q1 FY27 revenue of Rs 798 Cr (+19.1%) and PAT of Rs 170 Cr (+27.2%). Declared Rs 5 interim dividend.
Dr. Lal Path Labs Ltd.LALPATHLAB · Filed with the exchange
Strategic acquisitions include 80% of Sunshine Healthcare, Ghana (diagnostic business) and 30% of Neuome Technologies (innovative solutions).
No comments yet. Be the first.